US Food and Drug Administration Approves ZEPOSIA for Multiple Sclerosis

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s ZEPOSIA® (ozanimod), a New Oral Treatment for…

Bristol-Myers Squibb Presents Overall Survival and Safety Data From Pivotal CC-486 Study QUAZAR AML-001

(STL.News) – Bristol-Myers Squibb Company (NYSE: BMY) today announced clinical results from the QUAZAR AML-001 study,…

Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition

Company Has Now Satisfied All Regulatory Approvals for Celgene Acquisition Transaction Expected to Close on November…

Bristol-Myers Squibb-Pfizer Announce Randomized, Controlled Trial to study the Effect of Atrial Fibrillation Screening on older people Health

(STL.News) – The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study,…

Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

NEW YORK  (STL.News) Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration…

Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

New York (STL.News) – Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the…

Bristol-Myers Squibb Announces Agreement Between Celgene, Amgen to Divest OTEZLA® for $13.4 Billion

Agreement Contingent on FTC Consent Decree and Closing of Pending Bristol-Myers Squibb-Celgene Merger Pending Bristol-Myers Squibb-Celgene…